Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00515203
Other study ID # 20060195
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received August 9, 2007
Last updated July 18, 2014
Start date July 2007
Est. completion date August 2009

Study information

Verified date July 2014
Source Amgen
Contact n/a
Is FDA regulated No
Health authority Australia: Therapeutic Goods AdministrationCanada: Health CanadaFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)Spain: Agencia Española de Medicamentos y Productos SanitariosUnited States: Food and Drug AdministrationAustralia: Department of Health and Ageing Therapeutic Goods AdministrationAustralia: Human Research Ethics CommitteeUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of romiplostim (AMG 531) in the treatment of thrombocytopenia in pediatric subjects with chronic ITP. We will also evaluate the efficacy of romiplostim (AMG 531) and characterize the pharmacokinetics of romiplostim (AMG 531). It is anticipated that romiplostim (AMG 531), when given at an effective dose and schedule, will be well tolerated treatment for thrombocytopenia among pediatric subjects with chronic ITP.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date August 2009
Est. primary completion date March 2009
Accepts healthy volunteers No
Gender Both
Age group 1 Year to 17 Years
Eligibility Inclusion Criteria:

- Before any study-specific procedure, the appropriate written informed consent must be obtained. In addition to the written informed consent, the assent of the child from those subjects capable of providing assent must also be obtained if requested by the IRB/IEC.

- Diagnosis of ITP according to The American Society of Hematology (ASH) Guidelines at least six months prior to screening

- Age = 12 months and < 18 years at enrollment

- The mean of two platelet counts taken during the screening period must be = 30 x 10^9/L with no single count >35 x 10^9/L

- A serum creatinine concentration = 1.5 times the laboratory normal range (for each age category)

- Adequate liver function; serum bilirubin = 1.5 times the laboratory normal range

- Hemoglobin >10.0 g/dL

Exclusion Criteria:

- Known history of a bone marrow stem cell disorder (any abnormal bone marrow findings other than those typical of ITP must be approved by Amgen before a subject may be enrolled in the study)

- Known history of venous or arterial thrombotic or thromboembolic event

- Known history of congenital thrombocytopenia

- Known history of malignancy except basal cell carcinoma

- Known history of hepatitis B, hepatitis C, or HIV

- Known history of systemic lupus erythematosus, Evans Syndrome, or autoimmune neutropenia

- Known positive lupus anticoagulant or history of antiphospholipid antibody syndrome

- Known history of Disseminated Intravascular Coagulation, Hemolytic Uremic Syndrome, or Thrombotic Thrombocytopenic Purpura

- Currently receiving any treatment for ITP except for corticosteroids

- IV Ig or anti-D Ig within two weeks prior to the screening visit

- Rituximab (for any indication) within 14 weeks before the screening visit or anticipated use during the time of the proposed study

- Splenectomy within eight weeks of the screening visit

- Received hematopoietic growth factors including IL-11 (oprelvekin) within four weeks before the screening visit

- Received any alkylating agents within eight weeks before the screening visit or anticipated use during the time of the proposed study

- Subject is currently enrolled in or has not yet completed at least four weeks since ending other investigational device or drug trial(s), or subject is receiving investigational agent(s)

- Past or present participation in any study evaluating PEG-rHuMGDF, recombinant human thrombopoietin (rHuTPO), AMG 531, or related platelet product

- Pregnant (i.e. positive urine pregnancy test) or breast feeding

- Subject is not using adequate contraceptive precautions, if applicable.

- Known hypersensitivity to any recombinant E coli-derived product

- Subject has any kind of disorder that compromises the ability to comply with all study procedures

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Idiopathic Thrombocytopenic Purpura
  • Purpura
  • Purpura, Thrombocytopenic
  • Purpura, Thrombocytopenic, Idiopathic
  • Thrombocytopenia
  • Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
  • Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
  • Thrombocytosis

Intervention

Drug:
Placebo
Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.
AMG 531
Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Amgen

References & Publications (2)

Bussel J, Buchanan G, Nugent D, Gnarra D, Blanchette V, Nie K, Jun S. A randomized, double-blind, placebo-controlled phase 1/2 study to determine the safety and efficacy of romiplostim in children with chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). Blood;2011;118:28-36

Klaassen RJ, Mathias SD, Buchanan G, Bussel J, Deuson R, Young NL, Collier A, Bomgaars L, Blanchette V. Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). Pediatr Blood Cancer. 2012 Mar;58(3):395-8. doi: 10.1002/pbc.23312. Epub 2011 Sep 9. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse Events Occurrence of one or more adverse events in the participant during the 12-week treatment period 12 weeks Yes
Secondary Weeks With Platelet Count = 50 x 10^9/L The number of weeks with platelet count = 50 x 10^9/L during the 12 week treatment period. 12-week treatment period No
Secondary Bleeding Events (Grade 2 or Higher) Total number of bleeding events (Grade 2 or higher, i.e., mild to life-threatening, as defined in the protocol) for each participant during Weeks 2-13 (end-of-study visit for non-responders) 12-week treatment period (Weeks 2 - 13) No
Secondary Platelet Count = 50 x 10^9/L for Two Consecutive Weeks Participant incidence of achieving a platelet count =50 x 10^9/L for two consecutive weeks during the 12 week treatment period. 12-week treatment period No
Secondary Increase in Platelet Count = 20 x 10^9/L Above Baseline for Two Consecutive Weeks Participant incidence of achieving an increase in platelet count =20 x 10^9/L above baseline for two consecutive weeks during the 12 week treatment period. 12-week treatment period No
Secondary Requirement for Rescue Therapy (as Defined Per Protocol) Participant required rescue therapy (as defined per protocol) during the 12 week treatment period. 12-week treatment period No
See also
  Status Clinical Trial Phase
Completed NCT05220878 - Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP Phase 3
Completed NCT00451594 - High Dose Dexamethasone Vs. Conventional Dose Prednisolone in Adult ITP Phase 3
Withdrawn NCT01276561 - Single Incision Versus Standard Laparoscopic Splenectomy N/A
Completed NCT01713855 - Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura N/A
Recruiting NCT03465020 - Investigation on a Dynamic Cohort of Italian Patients With Active ITP
Completed NCT00603642 - P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura Phase 3
Completed NCT01143038 - Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim Phase 2
Not yet recruiting NCT04128358 - Triple Therapy in Patients With Idiopathic Thrombocytopenic Purpura : What is Behind? N/A
Completed NCT00128882 - Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D Phase 2
Completed NCT01525836 - rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP Phase 3
Completed NCT00888901 - Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag Phase 4
Completed NCT00828750 - Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Phase 3
Completed NCT00625443 - Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003 Phase 2
Completed NCT00475423 - A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura. Phase 2
Completed NCT00454857 - Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) N/A
Completed NCT00102323 - AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy Phase 3
Completed NCT05492409 - Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients Phase 3
Terminated NCT01433978 - A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura) Phase 3
Withdrawn NCT01443351 - Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP)
Completed NCT01520909 - Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. Phase 3